Loading...
•
Mar 31
Lantheus Q1 2025 Earnings Report
Lantheus reported financial results for Q1 2025 with slight revenue growth and solid adjusted EPS, amid acquisitions and product updates.
Key Takeaways
Lantheus delivered $372.8 million in revenue and $1.53 in non-GAAP EPS for Q1 2025, with strong free cash flow and continued strategic investments through acquisitions.
Revenue reached $372.8 million, a 0.8% increase from Q1 2024.
GAAP EPS dropped to $1.02 from $1.87 YoY, while adjusted EPS was $1.53.
Free cash flow totaled $98.8 million, reflecting strong cash generation.
Closed Evergreen Theragnostics acquisition and announced SPECT divestiture.
Lantheus
Lantheus
Lantheus Revenue by Segment
Revenue by Segment
PYLARIFY Sales Revenue
CapyFin.comDEFINITY Sales Revenue
CapyFin.comTechneLite Sales Revenue
CapyFin.comOther Precision Diagnostics Revenue
CapyFin.comStrategic Partnerships & Other Revenue
CapyFin.com Forward Guidance
Lantheus revised its FY2025 guidance with slightly adjusted revenue and reduced EPS projections amid ongoing acquisitions.
Positive Outlook
- Maintained strong cash position with $938.5 million in cash.
- Evergreen acquisition completed, boosting radiopharma pipeline.
- Planned NDA filing for MK-6240 expected in Q3 2025.
- Positive data from MK-6240 pivotal studies.
- Access to $750 million from revolving credit facility.
Challenges Ahead
- GAAP EPS and net income declined significantly year-over-year.
- Lowered adjusted EPS guidance for FY2025 to $6.60–$6.70 from prior $7.00–$7.20.
- SPECT business divestiture may reduce near-term revenue contributions.
- Ongoing challenges integrating acquisitions and managing pipeline investments.
- Potential volatility from equity securities investments.
Revenue & Expenses
Visualization of income flow from segment revenue to net income